ArticleAmerican journal of translational research2022
Diagnostic role of urinary CA-2 in urinary stones and its prediction of complications.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbonic anhydrase-2 (CA-2) is involved in the mineralization and calcification of organisms. Evidence suggests that CA-2 is associated with urolithiasis. However, the relationship between CA-2 and urinary stones remains unclear. The study aimed to assess the correlation of urinary CA-2 (uCA-2) level with the risk of urinary stones.
methodsA retrospective cohort study was conducted on patients with urinary stones and healthy subjects who presented to our hospital between March 2017 and November 2019 to determine the pretreatment uCA-2 level by enzyme linked immunosorbent assay (ELISA). Differences in uCA-2 levels between patients with urinary stones and healthy subjects were compared. Then, comparison between stone patients with complications and those without was carried out as well as correlation analysis to detect factors associated with biomarker expression.
resultsPatients with urinary stones (n=118) were designated the urinary stones group and healthy subjects (n=42) were designated the healthy control group. The mean pretreatment uCA-2 level was significantly higher in cases than in controls (P=0.028). Furthermore, the uCA-2 level had a positive correlation with urinary stone-associated complications (R=0.379, P<0.001), especially pain (R=0.524, P<0.001) and hematuria (R=0.374, P<0.001). Receiver operating characteristic curve (ROC) analysis revealed that a uCA-2 level threshold of 10.94 ng/mL had 83.67% sensitivity and 68.12% specificity for predicting complications in patients with urinary stones.
conclusionExcessive uCA-2 excretion is a major risk factor for urinary stones. Our findings suggest that uCA-2 may be used as a novel biomarker for the diagnosis of urinary stones and the prediction of its complications.
Indexed as
Identifiers
36628213PMC9827313W4315621474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.